Neurocrine Biosciences released positive Phase 2 data for NBI-1117568 in adults with schizophrenia, showing significant improvement with the 20 mg dose. Piper Sandler upgraded the stock rating, highlighting its potential in the antipsychotic field.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing